The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins

Atherosclerosis. 2011 Aug;217(2):395-400. doi: 10.1016/j.atherosclerosis.2011.04.001. Epub 2011 Apr 16.

Abstract

Objectives: Mimetic peptides of apolipoprotein A-I (apoA-I) present a new strategy for promoting the biological activity of high density lipoproteins (HDL). This study aimed to compare the anti-inflammatory effects of ETC-642, a new apoA-I mimetic peptide, with discoidal reconstituted HDL (rHDL).

Methods: New Zealand White rabbits (n=42) received daily infusions of saline, rHDL or discoidal complexes of an amphipathic peptide, ETC-642 (1-30 mg/kg), prior to insertion of non-occlusive carotid collars. Human coronary artery endothelial cells (HCAECs) were pre-incubated with ETC-642 or rHDL before TNF-α stimulation. Monocyte adhesion was investigated by pre-incubating HCAECs with rHDL or ETC-642, stimulating with TNF-α and incubating with THP-1 monocytes.

Results: Infusion of ETC-642 resulted in dose-dependent reductions of collar-induced expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in the artery wall (p<0.05). Pre-incubation of HCAECs with ETC-642 and rHDL reduced TNF-α-induced THP-1 monocyte adhesion (p<0.01). Furthermore, ETC-642 and rHDL treatment reduced TNF-α induced mRNA levels of inflammatory markers VCAM-1, fractalkine, MCP-1 and the p65 subunit of NF-κB (p<0.05).

Conclusion: These studies demonstrate that ETC-642 exhibits anti-inflammatory properties that are comparable to apoA-I both in vivo and in vitro and that these effects are mediated via the NF-κB signaling pathway.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1,2-Dipalmitoylphosphatidylcholine / administration & dosage
  • 1,2-Dipalmitoylphosphatidylcholine / pharmacology*
  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / pharmacology*
  • Apolipoprotein A-I / blood*
  • Carotid Artery Diseases / genetics
  • Carotid Artery Diseases / immunology
  • Carotid Artery Diseases / metabolism
  • Carotid Artery Diseases / prevention & control*
  • Chemokine CCL2 / genetics
  • Chemokine CX3CL1 / genetics
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Endothelial Cells / drug effects*
  • Endothelial Cells / immunology
  • Endothelial Cells / metabolism
  • Humans
  • Inflammation / genetics
  • Inflammation / immunology
  • Inflammation / metabolism
  • Inflammation / prevention & control*
  • Infusions, Intravenous
  • Intercellular Adhesion Molecule-1 / genetics
  • Intercellular Adhesion Molecule-1 / metabolism
  • Intercellular Signaling Peptides and Proteins
  • Lipoproteins / blood*
  • Lipoproteins, HDL / blood*
  • Molecular Mimicry
  • Monocytes / drug effects
  • Monocytes / immunology
  • Peptides / administration & dosage
  • Peptides / pharmacology*
  • RNA, Messenger / metabolism
  • Rabbits
  • Signal Transduction / drug effects
  • Sphingomyelins / administration & dosage
  • Sphingomyelins / pharmacology*
  • Transcription Factor RelA / genetics
  • Tumor Necrosis Factor-alpha / metabolism
  • Vascular Cell Adhesion Molecule-1 / genetics
  • Vascular Cell Adhesion Molecule-1 / metabolism

Substances

  • APOA1 protein, human
  • Anti-Inflammatory Agents
  • Apolipoprotein A-I
  • CCL2 protein, human
  • CX3CL1 protein, human
  • Chemokine CCL2
  • Chemokine CX3CL1
  • ESP 24218
  • ETC 642
  • Intercellular Signaling Peptides and Proteins
  • Lipoproteins
  • Lipoproteins, HDL
  • Peptides
  • RELA protein, human
  • RNA, Messenger
  • Sphingomyelins
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • Vascular Cell Adhesion Molecule-1
  • discoidal lipoproteins
  • Intercellular Adhesion Molecule-1
  • 1,2-Dipalmitoylphosphatidylcholine